Evaluation of Everolimus Activity Against Using In Vitro Models of Infection

Overview

Journal Antibiotics (Basel)

Specialty Pharmacology

Date 2023 Jan 21

PMID 36671372

Authors

Delia Mercedes Bianco

Flavio De Maio

Giulia Santarelli

Ivana Palucci

Alessandro Salustri

Giada Bianchetti

Giuseppe Maulucci

Franco Citterio

Maurizio Sanguinetti

Enrica Tamburrini

Michela Sali

Giovanni Delogu

Affiliations

Soon will be listed here.

Abstract

Even though Everolimus has been investigated in a phase II randomized trial as a host-directed therapy (HDT) to treat tuberculosis (TB), an oncological patient treated with Everolimus for a neuroendocrine pancreatic neoplasia developed active TB twice and a non-tuberculous mycobacterial (NTM) infection in a year and a half time span. To investigate this interesting case, we isolated and genotypically characterized the () clinical strain from the patient and tested the effect of Everolimus on its viability in an axenic culture and in a peripheral blood mononuclear cell (PBMCs) infection model. To exclude strain-specific resistance, we tested the activity of Everolimus against strains of ancient and modern lineages. Furthermore, we investigated the Everolimus effect on ROS production and autophagy modulation during infection. Everolimus did not have a direct effect on mycobacteria viability and a negligible effect during infection in host cells, although it stimulated autophagy and ROS production. Despite being a biologically plausible HDT against TB, Everolimus does not exert a direct or indirect activity on . This case underlines the need for a careful approach to drug repurposing and implementation and the importance of pre-clinical experimental studies.

Citing Articles

The advances in adjuvant therapy for tuberculosis with immunoregulatory compounds.

Mi J, Wu X, Liang J Front Microbiol. 2024; 15:1380848.

PMID: 38966394 PMC: 11222340. DOI: 10.3389/fmicb.2024.1380848.

Unraveling the potential of graphene quantum dots against infection.

Santarelli G, Perini G, Salustri A, Palucci I, Rosato R, Palmieri V Front Microbiol. 2024; 15:1395815.

PMID: 38774507 PMC: 11107295. DOI: 10.3389/fmicb.2024.1395815.

Host-directed therapy against mycobacterium tuberculosis infections with diabetes mellitus.

Zhao L, Fan K, Sun X, Li W, Qin F, Shi L Front Immunol. 2024; 14:1305325.

PMID: 38259491 PMC: 10800548. DOI: 10.3389/fimmu.2023.1305325.

Effects of Everolimus in Modulating the Host Immune Responses against Infection.

Raien A, Davis S, Zhang M, Zitser D, Lin M, Pitcher G Cells. 2023; 12(22).

PMID: 37998388 PMC: 10670413. DOI: 10.3390/cells12222653.

Pharmacomicrobiomics of Classical Immunosuppressant Drugs: A Systematic Review.

Manes A, Di Renzo T, Dodani L, Reale A, Gautiero C, Di Lauro M Biomedicines. 2023; 11(9).

PMID: 37761003 PMC: 10526314. DOI: 10.3390/biomedicines11092562.

References

Chen C, Liu C, Feng J, Loong C, Liu C, Hsia C . Incidence and Risk Factors for Tuberculosis After Liver Transplantation in an Endemic Area: A Nationwide Population-Based Matched Cohort Study. Am J Transplant. 2015; 15(8):2180-7. DOI: 10.1111/ajt.13235. View

Alipanah N, Jarlsberg L, Miller C, Linh N, Falzon D, Jaramillo E . Adherence interventions and outcomes of tuberculosis treatment: A systematic review and meta-analysis of trials and observational studies. PLoS Med. 2018; 15(7):e1002595. PMC: 6029765. DOI: 10.1371/journal.pmed.1002595. View

Gils T, Lynen L, de Jong B, Van Deun A, Decroo T . Pretomanid for tuberculosis: a systematic review. Clin Microbiol Infect. 2021; 28(1):31-42. DOI: 10.1016/j.cmi.2021.08.007. View

Kaufmann S, Dorhoi A, Hotchkiss R, Bartenschlager R . Host-directed therapies for bacterial and viral infections. Nat Rev Drug Discov. 2017; 17(1):35-56. PMC: 7097079. DOI: 10.1038/nrd.2017.162. View

Feuerriegel S, Schleusener V, Beckert P, Kohl T, Miotto P, Cirillo D . PhyResSE: a Web Tool Delineating Mycobacterium tuberculosis Antibiotic Resistance and Lineage from Whole-Genome Sequencing Data. J Clin Microbiol. 2015; 53(6):1908-14. PMC: 4432036. DOI: 10.1128/JCM.00025-15. View

Jeon S, Yhim H, Lee N, Song E, Kwak J, Yim C . Everolimus-induced activation of latent infection in a patient with metastatic renal cell carcinoma. Korean J Intern Med. 2016; 32(2):365-368. PMC: 5339459. DOI: 10.3904/kjim.2015.121. View

Wang M, Wu S, He J . Efficacy of bedaquiline in the treatment of drug-resistant tuberculosis: a systematic review and meta-analysis. BMC Infect Dis. 2021; 21(1):970. PMC: 8447831. DOI: 10.1186/s12879-021-06666-8. View

Maulucci G, Chiarpotto M, Papi M, Samengo D, Pani G, De Spirito M . Quantitative analysis of autophagic flux by confocal pH-imaging of autophagic intermediates. Autophagy. 2015; 11(10):1905-16. PMC: 4824579. DOI: 10.1080/15548627.2015.1084455. View

van Embden J, Cave M, Crawford J, Dale J, Eisenach K, Gicquel B . Strain identification of Mycobacterium tuberculosis by DNA fingerprinting: recommendations for a standardized methodology. J Clin Microbiol. 1993; 31(2):406-9. PMC: 262774. DOI: 10.1128/jcm.31.2.406-409.1993. View

10.

Kerner G, Laval G, Patin E, Boisson-Dupuis S, Abel L, Casanova J . Human ancient DNA analyses reveal the high burden of tuberculosis in Europeans over the last 2,000 years. Am J Hum Genet. 2021; 108(3):517-524. PMC: 8008489. DOI: 10.1016/j.ajhg.2021.02.009. View

11.

Mahalati K, Kahan B . Clinical pharmacokinetics of sirolimus. Clin Pharmacokinet. 2001; 40(8):573-85. DOI: 10.2165/00003088-200140080-00002. View

12.

Wallis R, Ginindza S, Beattie T, Arjun N, Likoti M, Edward V . Adjunctive host-directed therapies for pulmonary tuberculosis: a prospective, open-label, phase 2, randomised controlled trial. Lancet Respir Med. 2021; 9(8):897-908. PMC: 8332197. DOI: 10.1016/S2213-2600(20)30448-3. View

13.

Pushpakom S, Iorio F, Eyers P, Jane Escott K, Hopper S, Wells A . Drug repurposing: progress, challenges and recommendations. Nat Rev Drug Discov. 2018; 18(1):41-58. DOI: 10.1038/nrd.2018.168. View

14.

Guirao-Arrabal E, Santos F, Redel-Montero J, Vaquero J, Cantisan S, Vidal E . Risk of tuberculosis after lung transplantation: the value of pretransplant chest computed tomography and the impact of mTOR inhibitors and azathioprine use. Transpl Infect Dis. 2016; 18(4):512-9. DOI: 10.1111/tid.12555. View

15.

Ranjbar S, Haridas V, Nambu A, Jasenosky L, Sadhukhan S, Ebert T . Cytoplasmic RNA Sensor Pathways and Nitazoxanide Broadly Inhibit Intracellular Mycobacterium tuberculosis Growth. iScience. 2019; 22:299-313. PMC: 6909047. DOI: 10.1016/j.isci.2019.11.001. View

16.

Fijalkowska-Morawska J, Jagodzinska M, Nowicki M . Pulmonary embolism and reactivation of tuberculosis during everolimus therapy in a kidney transplant recipient. Ann Transplant. 2012; 16(4):107-10. DOI: 10.12659/aot.882226. View

17.

Horne D, Graustein A, Shah J, Peterson G, Savlov M, Steele S . Human ULK1 Variation and Susceptibility to Mycobacterium tuberculosis Infection. J Infect Dis. 2016; 214(8):1260-7. PMC: 5034956. DOI: 10.1093/infdis/jiw347. View

18.

Ashley D, Hernandez J, Cao R, To K, Yegiazaryan A, Abrahem R . Antimycobacterial Effects of Everolimus in a Human Granuloma Model. J Clin Med. 2020; 9(7). PMC: 7409120. DOI: 10.3390/jcm9072043. View

19.

Stucki D, Brites D, Jeljeli L, Coscolla M, Liu Q, Trauner A . Mycobacterium tuberculosis lineage 4 comprises globally distributed and geographically restricted sublineages. Nat Genet. 2016; 48(12):1535-1543. PMC: 5238942. DOI: 10.1038/ng.3704. View

20.

Berger S, Sommerer C, Witzke O, Tedesco H, Chadban S, Mulgaonkar S . Two-year outcomes in de novo renal transplant recipients receiving everolimus-facilitated calcineurin inhibitor reduction regimen from the TRANSFORM study. Am J Transplant. 2019; 19(11):3018-3034. DOI: 10.1111/ajt.15480. View